• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 4:02:55 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LTRN alert in real time by email
    SC 13G 1 d347206dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    (Amendment No.     )*

    Under the Securities Exchange Act of 1934

     

     

    Lantern Pharma Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    51654W101

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 51654W101    13G    Page 2 of 17 Pages

     

      1   

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Green Park & Golf Ventures II, LLC (see Item 2(a))

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Texas

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    -0-

       6   

    SHARED VOTING POWER

     

    147,502 (see Item 4(a))*

       7   

    SOLE DISPOSITIVE POWER

     

    -0-

       8   

    SHARED DISPOSITIVE POWER

     

    147,502 (see Item 4(a))*

      9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    147,502 (see Item 4(a))*

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.4% (see Item 4(b))**

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    *

    This calculation is based upon (i) 131,697 shares of Common Stock (as defined below) held directly by Lantern 3-19 (as defined below) and (ii) 15,805 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by Lantern 3-19.

    **

    This calculation is rounded to the nearest tenth and is based upon 10,519,097 shares of Common Stock issued and outstanding as of February 13, 2021, an amount determined by adding (i) 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement (as defined below), plus (ii) 15,805 shares of Common Stock issuable upon the exercise of outstanding warrants directly held by Lantern 3-19.


    CUSIP No. 51654W101    13G    Page 3 of 17 Pages

     

      1   

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Green Park & Golf Ventures, LLC (see Item 2(a))

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Texas

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    -0-

       6   

    SHARED VOTING POWER

     

    525,256 (see Item 4(a))*

       7   

    SOLE DISPOSITIVE POWER

     

    -0-

       8   

    SHARED DISPOSITIVE POWER

     

    525,256 (see Item 4(a))*

      9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    525,256 (see Item 4(a))*

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.0% (see Item 4(b))**

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    *

    This calculation is based upon (i) 292,605 shares of Common Stock (as defined below) held directly by GPG LPI (as defined below), (ii) 211,291 shares of Common Stock held directly by HWF II (as defined below), and (iii) 21,360 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by GPG LPI (as defined below).

    **

    This calculation is rounded to the nearest tenth and is based upon 10,524,652 shares of Common Stock issued and outstanding as of February 13, 2021, an amount determined by adding (i) 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement (as defined below), plus (ii) 21,360 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by GPG LPI.


    CUSIP No. 51654W101    13G    Page 4 of 17 Pages

     

      1   

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    GPG LPI Investment, LLC (see Item 2(a))

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Texas

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    -0-

       6   

    SHARED VOTING POWER

     

    313,965 (see Item 4(a))*

       7   

    SOLE DISPOSITIVE POWER

     

    -0-

       8   

    SHARED DISPOSITIVE POWER

     

    313,965 (see Item 4(a))*

      9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    313,965 (see Item 4(a))*

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.0% (see Item 4(b))**

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    *

    This calculation is based upon (i) 292,605 shares of Common Stock (as defined below) held directly by GPG LPI (as defined below) and (ii) 21,360 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by GPG LPI.

    **

    This calculation is rounded to the nearest tenth and is based upon 10,524,652 shares of Common Stock issued and outstanding as of February 13, 2021, an amount determined by adding (i) 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement (as defined below), plus (ii) 21,360 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by GPG LPI.


    CUSIP No. 51654W101    13G    Page 5 of 17 Pages

     

      1   

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Lantern 3-19 Investment, LLC (see Item 2(a))

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Texas

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    -0-

       6   

    SHARED VOTING POWER

     

    147,502 (see Item 4(a))*

       7   

    SOLE DISPOSITIVE POWER

     

    -0-

       8   

    SHARED DISPOSITIVE POWER

     

    147,502 (see Item 4(a))*

      9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    147,502 (see Item 4(a))*

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.4% (see Item 4(b))**

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    *

    This calculation is based upon (i) 131,697 shares of Common Stock (as defined below) held directly by Lantern 3-19 (as defined below) and (ii) 15,805 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by Lantern 3-19.

    **

    This calculation is rounded to the nearest tenth and is based upon 10,519,097 shares of Common Stock issued and outstanding as of February 13, 2021, an amount determined by adding (i) 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement (as defined below), plus (ii) 15,805 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by Lantern 3-19.


    CUSIP No. 51654W101    13G    Page 6 of 17 Pages

     

      1   

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Health Wildcatters Fund II, LLC (see Item 2(a))

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Texas

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    -0-

       6   

    SHARED VOTING POWER

     

    211,291 (see Item 4(a))

       7   

    SOLE DISPOSITIVE POWER

     

    -0-

       8   

    SHARED DISPOSITIVE POWER

     

    211,291 (see Item 4(a))

      9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    211,291 (see Item 4(a))

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    2.0% (see Item 4(b))**

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    **

    This calculation is rounded to the nearest tenth and is based upon 10,503,292 shares of Common Stock (as defined below) issued and outstanding as of February 13, 2021, as represented in the Prospectus Supplement (as defined below).


    CUSIP No. 51654W101    13G    Page 7 of 17 Pages

     

      1   

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Health Wildcatters, LLC (see Item 2(a))

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Texas

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    -0-

       6   

    SHARED VOTING POWER

     

    211,291 (see Item 4(a))*

       7   

    SOLE DISPOSITIVE POWER

     

    -0-

       8   

    SHARED DISPOSITIVE POWER

     

    211,291 (see Item 4(a))*

      9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    211,291 (see Item 4(a))*

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    2.0% (see Item 4(b))**

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    *

    This amount is based upon 211,291 shares of Common Stock (as defined below) directly held by HWF II (as defined below).

    **

    This calculation is rounded to the nearest tenth and is based upon 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement (as defined below).


    CUSIP No. 51654W101    13G    Page 8 of 17 Pages

     

      1   

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Carl D. Soderstrom (see Item 2(a))

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    -0-

       6   

    SHARED VOTING POWER

     

    672,758 (see Item 4(a))*

       7   

    SOLE DISPOSITIVE POWER

     

    -0-

       8   

    SHARED DISPOSITIVE POWER

     

    672,758 (see Item 4(a))*

      9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    672,758 (see Item 4(a))*

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.4% (see Item 4(b))**

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    *

    This calculation is based upon (i) 292,605 shares of Common Stock (as defined below) held directly by GPG LPI (as defined below), (ii) 211,291 shares of Common Stock held directly by HWF II (as defined below), (iii) 131,697 shares of Common Stock held directly by Lantern 3-19 (as defined below), (iv) 15,805 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by Lantern 3-19, and (v) 21,360 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by GPG LPI.

    **

    This calculation is rounded to the nearest tenth and is based upon 10,540,457 shares of Common Stock issued and outstanding as of February 13, 2021, an amount determined by adding (i) 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement (as defined below), plus (ii) 15,805 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by Lantern 3-19, plus (iii) 21,360 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by GPG LPI.


    CUSIP No. 51654W101    13G    Page 9 of 17 Pages

     

      1   

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Clay M. Heighten, M.D. (see Item 2(a))

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    -0-

       6   

    SHARED VOTING POWER

     

    672,758 (see Item 4(a))*

       7   

    SOLE DISPOSITIVE POWER

     

    -0-

       8   

    SHARED DISPOSITIVE POWER

     

    672,758 (see Item 4(a))*

      9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    672,758 (see Item 4(a))*

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.4% (see Item 4(b))**

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    *

    This calculation is based upon (i) 292,605 shares of Common Stock (as defined below) held directly by GPG LPI (as defined below), (ii) 211,291 shares of Common Stock held directly by HWF II (as defined below), (iii) 131,697 shares of Common Stock held directly by Lantern 3-19 (as defined below), (iv) 15,805 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by Lantern 3-19, and (v) 21,360 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by GPG LPI.

    **

    This calculation is rounded to the nearest tenth and is based upon 10,540,457 shares of Common Stock issued and outstanding as of February 13, 2021, an amount determined by adding (i) 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement (as defined below), plus (ii) 15,805 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by Lantern 3-19, plus (iii) 21,360 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by GPG LPI.


    CUSIP No. 51654W101    13G    Page 10 of 17 Pages

     

      1   

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Gilbert G. Garcia II (see Item 2(a))

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

    SOLE VOTING POWER

     

    -0-

       6   

    SHARED VOTING POWER

     

    147,502 (see Item 4(a))*

       7   

    SOLE DISPOSITIVE POWER

     

    -0-

       8   

    SHARED DISPOSITIVE POWER

     

    147,502 (see Item 4(a))*

      9   

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    147,502 (see Item 4(a))*

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.4% (see Item 4(b))**

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    *

    This calculation is based upon (i) 131,697 shares of Common Stock (as defined below) held directly by Lantern 3-19 (as defined below) and (ii) 15,805 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by Lantern 3-19.

    **

    This calculation is rounded to the nearest tenth and is based upon 10,519,097 shares of Common Stock issued and outstanding as of February 13, 2021, an amount determined by adding (i) 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement (as defined below), plus (ii) 15,805 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by Lantern 3-19.


    CUSIP No. 51654W101    13G    Page 11 of 17 Pages

     

     

    Item 1(a).

    Name of Issuer:

    Lantern Pharma Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    The Issuer’s principal executive office is located at 1920 McKinney Avenue, 7th Floor, Dallas, Texas, 75201.

     

    Item 2(a).

    Name of Person Filing:

    This Schedule 13G is filed on behalf of the following persons (collectively, the “Reporting Persons”): (i) Carl D. Soderstrom, a resident of the State of Texas; (ii) Clay M. Heighten, M.D., a resident of the State of Texas; (iii) Gilbert G. Garcia II, a resident of the State of Texas; (iv) Green Park & Golf Ventures, LLC, a Texas limited liability company (“GPG”); (v) Green Park & Golf Ventures II, LLC, a Texas limited liability company (“GPG II”); (vi) Health Wildcatters, LLC, a Texas limited liability company (“HW”); (vii) Health Wildcatters Fund II, LLC, a Texas limited liability company (“HWF II”); (viii) GPG LPI Investment, LLC, a Texas limited liability company (“GPG LPI”); and (ix) Lantern 3-19 Investment, LLC, a Texas limited liability company (“Lantern 3-19”).

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

    The principal business office for each of the Reporting Persons is 5910 N. Central Expy., Suite 1400, Dallas, Texas 75206.

     

    Item 2(c).

    Citizenship:

    Citizenship information is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d).

    Title of Class of Securities:

    Common stock, $0.0001 par value (“Common Stock”).

     

    Item 2(e).

    CUSIP Number:

    51654W101

     

    Item 3

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:  ☐

    This Item 3 is not applicable.


    CUSIP No. 51654W101    13G    Page 12 of 17 Pages

     

    Item 4

    Ownership:

     

    (a)-(c)

    The following table sets forth the amount of Common Stock beneficially owned by each of the Reporting Persons through February 13, 2021:

     

         Shares Beneficially
    Owned
         Percent of Class4*  

    1. Green Park & Golf Ventures II, LLC

      

    Sole Voting Power

         -0-        0 % 

    Shared Voting Power

         147,502        1.4 % 

    Sole Dispositive Power

         -0-        0 % 

    Shared Dispositive Power

         147,502        1.4 % 

    Aggregate Voting and Dispositive Power

         147,502        1.4 % 

    2. Green Park & Golf Ventures, LLC

      

    Sole Voting Power

         -0-        0 % 

    Shared Voting Power

         525,256        5.0 % 

    Sole Dispositive Power

         -0-        0 % 

    Shared Dispositive Power

         525,256        5.0 % 

    Aggregate Voting and Dispositive Power

         525,256        5.0 % 

    3. Health Wildcatters, LLC

      

    Sole Voting Power

         -0-        0 % 

    Shared Voting Power

         211,291        2.0 % 

    Sole Dispositive Power

         -0-        0 % 

    Shared Dispositive Power

         211,291        2.0 % 

    Aggregate Voting and Dispositive Power

         211,291        2.0 % 

    4. Health Wildcatters Fund II, LLC1

      

    Sole Voting Power

         -0-        0 % 

    Shared Voting Power

         211,291        2.0 % 

    Sole Dispositive Power

         -0-        0 % 

    Shared Dispositive Power

         211,291        2.0 % 

    Aggregate Voting and Dispositive Power

         211,291        2.0 % 

    5. GPG LPI Investment, LLC2

      

    Sole Voting Power

         -0-        0 % 


    CUSIP No. 51654W101    13G    Page 13 of 17 Pages

     

    Shared Voting Power

         313,965        3.0 % 

    Sole Dispositive Power

         -0-        0 % 

    Shared Dispositive Power

         313,965        3.0 % 

    Aggregate Voting and Dispositive Power

         313,965        3.0 % 

    6. Lantern 3-19 Investment, LLC3

      

    Sole Voting Power

         -0-        0 % 

    Shared Voting Power

         147,502        1.4 % 

    Sole Dispositive Power

         -0-        0 % 

    Shared Dispositive Power

         147,502        1.4 % 

    Aggregate Voting and Dispositive Power

         147,502        1.4 % 

    7. Carl D. Soderstrom

      

    Sole Voting Power

         -0-        0 % 

    Shared Voting Power

         672,758        6.4 % 

    Sole Dispositive Power

         -0-        0 % 

    Shared Dispositive Power

         672,758        6.4 % 

    Aggregate Voting and Dispositive Power

         672,758        6.4 % 

    8. Clay M. Heighten, M.D.

      

    Sole Voting Power

         -0-        0 % 

    Shared Voting Power

         672,758        6.4 % 

    Sole Dispositive Power

         -0-        0 % 

    Shared Dispositive Power

         672,758        6.4 % 

    Aggregate Voting and Dispositive Power

         672,758        6.4 % 

    9. Gilbert G. Garcia II

      

    Sole Voting Power

         -0-        0 % 

    Shared Voting Power

         147,502        1.4 % 

    Sole Dispositive Power

         -0-        0 % 

    Shared Dispositive Power

         147,502        1.4 % 

    Aggregate Voting and Dispositive Power

         147,502        1.4 % 

     

    1

    These securities are directly held by HWF II. Carl D. Soderstrom and Clay M. Heighten, M.D. are the managing members of GPG, which is the managing member of HW, which is the managing member of HWF II. Therefore, Carl D. Soderstrom, Clay M. Heighten, M.D., GPG, and HW may be deemed to beneficially own these securities.

    2

    These securities are directly held by GPG LPI. Carl D. Soderstrom and Clay M. Heighten, M.D. are the managing members of GPG, which is the managing member GPG LPI. Therefore, Carl D. Soderstrom, Clay M. Heighten, M.D., and GPG may be deemed to beneficially own these securities.


    CUSIP No. 51654W101    13G    Page 14 of 17 Pages

     

    3

    These securities are directly held by Lantern 3-19. Carl D. Soderstrom, Clay M. Heighten, M.D., and Gilbert G. Garcia II are the managing members of GPG II, which is the managing member of Lantern 3-19. Therefore, Carl D. Soderstrom, Clay M. Heighten, M.D., Gilbert G. Garcia II, and GPG II may be deemed to beneficially own these securities.

     

    4

    With respect to the amount of shares of Common Stock beneficially owned by GPG II, this calculation is rounded to the nearest tenth and is based upon 10,519,097 shares of Common Stock issued and outstanding as of February 13, 2021, an amount determined by adding (i) 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement on Form 424(b)(4) (the “Prospectus Supplement”) filed with the Securities and Exchange Commission (the “SEC”) on January 15, 2021 (File No. 001-39318), plus (ii) 15,805 shares of Common Stock issuable upon the exercise of outstanding warrants directly held by Lantern 3-19.

    With respect to the amount of shares of Common Stock beneficially owned by GPG, this calculation is rounded to the nearest tenth and is based upon 10,524,652 shares of Common Stock issued and outstanding as of February 13, 2021, an amount determined by adding (i) 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement, plus (ii) 21,360 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by GPG LPI.

    With respect to the amount of shares of Common Stock beneficially owned by GPG LPI, this calculation is rounded to the nearest tenth and is based upon 10,524,652 shares of Common Stock issued and outstanding as of February 13, 2021, an amount determined by adding (i) 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement, plus (ii) 21,360 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by GPG LPI.

    With respect to the amount of shares of Common Stock beneficially owned by Lantern 3-19, this calculation is rounded to the nearest tenth and is based upon 10,519,097 shares of Common Stock issued and outstanding as of February 13, 2021, an amount determined by adding (i) 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement, plus (ii) 15,805 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by Lantern 3-19.

    With respect to the amount of shares of Common Stock beneficially owned by HWF II, this calculation is rounded to the nearest tenth and is based upon 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement.

    With respect to the amount of shares of Common Stock beneficially owned by HW, this calculation is rounded to the nearest tenth and is based upon 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement.

    With respect to the amount of shares of Common Stock beneficially owned by Carl D. Soderstrom, this calculation is rounded to the nearest tenth and is based upon 10,540,457 shares of Common Stock issued and outstanding as of February 13, 2021, an amount determined by adding (i) 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement, plus (ii) 15,805 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by Lantern 3-19, plus (iii) 21,360 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by GPG LPI

    With respect to the amount of shares of Common Stock beneficially owned by Clay M. Heighten, M.D., this calculation is rounded to the nearest tenth and is based upon 10,540,457 shares of Common Stock issued and outstanding as of February 13, 2021, an amount determined by adding (i) 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement, plus (ii) 15,805 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by Lantern 3-19, plus (iii) 21,360 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by GPG LPI.

    With respect to the amount of shares of Common Stock beneficially owned by Gilbert G. Garcia II, this calculation is rounded to the nearest tenth and is based upon 10,519,097 shares of Common Stock issued and outstanding as of February 13, 2021, an amount determined by adding (i) 10,503,292 shares of Common Stock issued and outstanding as of January 14, 2021, as represented in the Prospectus Supplement, plus (ii) 15,805 shares of Common Stock issuable upon the exercise of outstanding warrants held directly by Lantern 3-19.

     

    *

    As described in the Prospectus Supplement, the amount of shares of Common Stock issued and outstanding excludes (i) an over-allotment option granted to the underwriters under the Prospectus Supplement to purchase up to 642,856 additional shares of Common Stock, (ii) 820,608 shares of Common Stock issuable upon exercise of outstanding stock options, (iii) 550,099 shares of Common Stock reserved under the Issuer’s Amended and Restated 2018 Equity Incentive Plan, and (iv) shares of Common Stock issuable upon the exercise of outstanding warrants (except for those beneficially owned by any of the Reporting Persons and encompassed within this Schedule 13G).

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ☐


    CUSIP No. 51654W101    13G    Page 15 of 17 Pages

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    See Item 2(a) above, which is incorporated by reference in its entirety under this Item 6.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    CUSIP No. 51654W101    13G    Page 16 of 17 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 16, 2021

     

    GREEN PARK & GOLF VENTURES II, LLC
    By:  

    /s/ Gilbert G. Garcia II

      Name: Gilbert G. Garcia II
      Title: Manager

     

    GREEN PARK & GOLF VENTURES, LLC
    By:  

    /s/ Gilbert G. Garcia II

      Name: Gilbert G. Garcia II
      Title: Principal

     

    GPG LPI INVESTMENT, LLC
    By:  

    /s/ Gilbert G. Garcia II

      Name: Gilbert G. Garcia II
      Title: Principal of Green Park & Golf Ventures, LLC, the Managing Member of GPG LPI Investment, LLC

     

    LANTERN 3-19 INVESTMENT, LLC
    By:  

    /s/ Gilbert G. Garcia II

      Name: Gilbert G. Garcia II
      Title: Principal of Green Park & Golf Ventures II, LLC, the Managing Member of Lantern 3-19 Investment, LLC

     

    HEALTH WILDCATTERS FUND II, LLC
    By:  

    /s/ Gilbert G. Garcia II

      Name: Gilbert G. Garcia II
      Title: Principal of Green Park & Golf Ventures, LLC, the Managing Member of Health Wildcatters, LLC, the Managing Member of Health Wildcatters Fund II, LLC

     

    HEALTH WILDCATTERS, LLC
    By:  

    /s/ Gilbert G. Garcia II

      Name: Gilbert G. Garcia II
      Title: Principal of Green Park & Golf Ventures, LLC, the Managing Member of Health Wildcatters, LLC
    By:  

    /s/ Carl D. Soderstrom

      Carl D. Soderstrom
    By:  

    /s/ Clay M. Heighten, M.D.

      Clay M. Heighten, M.D.
    By:  

    /s/ Gilbert G. Garcia II

      Gilbert G. Garcia II


    CUSIP No. 51654W101    13G    Page 17 of 17 Pages

     

    JOINT FILING AGREEMENT

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

    DATED: February 16, 2021

     

    GREEN PARK & GOLF VENTURES II, LLC
    By:  

    /s/ Gilbert G. Garcia II

      Name: Gilbert G. Garcia II
      Title: Manager
    GREEN PARK & GOLF VENTURES, LLC
    By:  

    /s/ Gilbert G. Garcia II

      Name: Gilbert G. Garcia II
      Title: Principal
    GPG LPI INVESTMENT, LLC
    By:  

    /s/ Gilbert G. Garcia II

      Name: Gilbert G. Garcia II
      Title: Principal of Green Park & Golf Ventures, LLC, the Managing Member of GPG LPI Investment, LLC
    LANTERN 3-19 INVESTMENT, LLC
    By:  

    /s/ Gilbert G. Garcia II

      Name: Gilbert G. Garcia II
      Title: Principal of Green Park & Golf Ventures II, LLC, the Managing Member of Lantern 3-19 Investment, LLC
    HEALTH WILDCATTERS FUND II, LLC
    By:  

    /s/ Gilbert G. Garcia II

      Name: Gilbert G. Garcia II
      Title: Principal of Green Park & Golf Ventures, LLC, the Managing Member of Health Wildcatters, LLC, the Managing Member of Health Wildcatters Fund II, LLC
    HEALTH WILDCATTERS, LLC
    By:  

    /s/ Gilbert G. Garcia II

      Name: Gilbert G. Garcia II
      Title: Principal of Green Park & Golf Ventures, LLC, the Managing Member of Health Wildcatters, LLC
    By:  

    /s/ Carl D. Soderstrom

      Carl D. Soderstrom
    By:  

    /s/ Clay M. Heighten, M.D.

      Clay M. Heighten, M.D.
    By:  

    /s/ Gilbert G. Garcia II

      Gilbert G. Garcia II
    Get the next $LTRN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LTRN

    DatePrice TargetRatingAnalyst
    3/11/2022$34.00 → $36.00Buy
    HC Wainwright & Co.
    11/2/2021$32.00 → $34.00Buy
    HC Wainwright & Co.
    10/7/2021$32.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LTRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Schalop Lee Troy

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    8/20/25 6:25:16 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Schalop Lee Troy

    3 - Lantern Pharma Inc. (0001763950) (Issuer)

    7/30/25 5:20:47 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Fletcher Aaron G.L. sold $123,600 worth of shares (40,000 units at $3.09) (SEC Form 4)

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    6/13/25 7:57:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Lantern Pharma with a new price target

    HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $36.00 from $34.00 previously

    3/11/22 6:29:59 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Lantern Pharma with a new price target

    HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $34.00 from $32.00 previously

    11/2/21 6:34:51 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Lantern Pharma with a new price target

    HC Wainwright & Co. initiated coverage of Lantern Pharma with a rating of Buy and set a new price target of $32.00

    10/7/21 8:16:17 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates

    Major milestone achieved with successful completion of enrollment for LP-184 Phase 1a clinical trial, with 65 patients enrolled across a range of solid tumors including glioblastoma (GBM); LP-184 is a potential blockbuster drug-candidate with market potential of $10-12 billion USD in annual revenue. Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) established for LP-184, enabling advancement to upcoming Phase 1b/2 trials being planned for recurrent triple negative breast cancer (TNBC) and recurrent bladder cancer. Remarkable complete response observed in HARMONIC™ Trial patient: A 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) demonstrated a co

    8/13/25 4:30:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

    Novel combination therapy with STAR-001 targets the most aggressive and deadliest forms of brain cancer at first progression GBM represents an annual market opportunity of $3 to $5 billion USD with an accelerating number of cases globally Lantern Pharma has previously received both FDA Orphan and Fast Track Designations in GBM Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma Inc. (NASDAQ:LTRN), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase Ib/2a clinical trial to evaluate STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme (GBM) at

    8/6/25 8:30:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™

    Industry-Leading Platform Achieves 94% Accuracy with Real-Time Machine Learning, Providing Open-Access to Critical CNS Drug Development Technology Additional Predictive, Analytic and Descriptive Modules are Planned for Release Leveraging Lantern's Large-Scale Molecular Features Data Lake and Proprietary Ensemble Algorithmic Approach Lantern Pharma Inc. (NASDAQ:LTRN), a pioneering artificial intelligence company transforming oncology drug discovery and development, today announced the public release of its AI module for predicting blood-brain barrier (BBB) permeability of small molecules with unprecedented accuracy and scalability – predictBBB.ai™. This critical advancement addresses

    8/4/25 8:55:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    SEC Filings

    View All

    Lantern Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lantern Pharma Inc. (0001763950) (Filer)

    8/13/25 4:15:50 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Lantern Pharma Inc.

    10-Q - Lantern Pharma Inc. (0001763950) (Filer)

    8/13/25 4:06:50 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Lantern Pharma Inc.

    DEF 14A - Lantern Pharma Inc. (0001763950) (Filer)

    8/8/25 5:17:38 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Financials

    Live finance-specific insights

    View All

    Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

    Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025. Additional patient data readout from the HARMONIC™ Trial evaluating LP-300 in never-smokers with non-small cell lung cancer (NSCLC) anticipated in Q3 2025, including initial readout for patients from the Asian expansion cohort. Strengthened AI intellectual property portfolio with PCT publication of proprietary blood-brain barrier penetration prediction patent application; favorable PCT search report indicated no significant prior art. Expanded RADR® platform with innovative AI-powered module to improve the precision, cost and timeline of antibody

    5/15/25 8:45:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

    Webcast to be held Thursday, May 15th, 9:00 a.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its first quarter 2025 operating and financial results webcast on Thursday, May 15, 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. Management intends to discuss the operating and financial results for the first quarter ended March 31, 2025 and provide guidance on upcoming milestones, clinical tria

    5/8/25 8:30:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

    HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati

    3/27/25 4:01:00 PM ET
    $ACTU
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

    SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)

    3/1/24 4:10:40 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lantern Pharma Inc. (Amendment)

    SC 13G/A - Lantern Pharma Inc. (0001763950) (Subject)

    2/14/24 4:05:49 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

    SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)

    12/1/23 6:02:25 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Leadership Updates

    Live Leadership Updates

    View All

    Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

    Seasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member

    7/28/25 8:00:00 AM ET
    $CMRX
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives

    DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company's clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where his responsibilities will include oversight of drug candidate manufacturing and quality control. Darlene Bunpian, MPH has been appointed Clinical Trial Project Manag

    9/2/21 8:59:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care